Resources

In this blog, the BIA's Senior Policy and Public Affairs Manager, Dr Emma Lawrence, discusses the life science implications of Lord Darzi's review.

PACE has launched its second funding round, with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of AMR.

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has appointed a new Non-Executive Director to its board, Dr Hsin Loke. 

Financing led by Ahren, OMX Ventures and Paladin Capital Group represents one of the largest UK biotech Series A rounds in recent years.

Recent research indicates that the rate of global warming caused by human activity is at an all-time high. In response, Pioneer Group, a specialist in life science infrastructure and venture building, is ramping up its support for start-up businesses tackling planetary health challenges.

Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma. The multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies.

The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has today announced the first cohort of awardees of its Collaborative Discovery Programme (CDP) funding.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, discusses the recent Techbio Boost event hosted by KQ Labs and the BIA, highlighting the programme's role in supporting the growth of London-based techbio seed and pre-series A companies.

The political party conference season is in full swing, and the BIA is out in force in Liverpool for the Labour Party conference this week. I'm heartened to see the focus in ministerial speeches and the fringe on topics close to our hearts. Read on for updates on the Lib Dem conference, West Streeting speech and Invest in Women Taskforce.

LinkGevity has been selected to receive a highly competitive Women TechEU grant. This prestigious award, funded by Horizon Europe, highlights the groundbreaking nature of LinkGevity's work and positions the company among Europe's most promising deep tech startups.

In this blog, Dr Emma Lawrence, Senior Policy and Public Affairs Manager, BIA, shares more about the launch of our new inaugural Data, AI and Genomics Advisory Committee, a key initiative to support the growing techbio community in the UK.

This development will improve clinical trial infrastructure.

Research conducted by Pioneer Group sheds light on the current investment trends shaping the life sciences landscape, offering insights into where capital is being allocated and what it means for the sector.

STEaPP’s PIU together with VaxHub Global and VaxHub Sustainable hosted the VaxHub Futures Forum on Pandemic Preparedness during UCL’s Festival of Engineering. The event brought together over 50 participants from academia, government, industry, funding and advisory bodies to showcase the hubs’ vaccine manufacturing research and explore potential future scenarios for pandemic preparedness through the Futures Forum methodology, developed by Dr Ine Steenmans. The Futures Forum is an innovative and adaptable knowledge exchange format which uses ‘futures thinking’ to guide participants through a joint exploration of futures of a particular policy topic.

With a little over eight weeks to go to London Life Sciences Week (LLSW), we are launching a new website - lifesciencesweek.london - and lifting the lid on all that is happening to make the UK the place to be for life sciences this November. Continue reading for updates on NHS, £12 million Innovate UK funding, and more!